FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

Washington, D.C. 20549	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							<i>'</i>											
Name and Address of Reporting Person* O'Keeffe Charles B					2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC.								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
O Reelle Charles B				16	[CPRX]								X	Directo	r		10% Ov	ner
(Last)	(Fi	irst) ((Middle)	[_	[CIRA]							_	Officer below)	(give title		Other (s below)	pecify	
355 ALHAMBRA CIRCLE, SUITE 801					3. Date of Earliest Transaction (Month/Day/Year) 12/06/2022													
(Street)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
GABLES	S FI		33134										X		rm filed by One Reporting Person rm filed by More than One Reporting			
(City)	(S	tate) ((Zip)	_									Persor	1		·		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				Transaction ate lonth/Day/Y	Exection Day/Year) if any		2A. Deemed Execution Date, if any (Month/Day/Year)		actior (Instr			ired (A nstr. 3,	4 and Securiti Benefic Owned		es Forn ially (D) c Following (I) (II		r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A) or (D) Pr		rice	Reporter Transactions (Instr. 3	tion(s)			Instr. 4)
Common Stock, par value \$0.001 per share 12			12/06/202	/2022		М		1,33	1,334 A		(1)	566,391			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code	action (Instr.	n of		Expiration	6. Date Exercisable ar Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			s. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or	ount mber ires					
Restricted Stock Units	(1)	12/06/2022		М			1,334	(2)		(3)	Commor	1,3	334	\$0	295,50	0	D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- 2. Derivative securities vested in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022.
- 3. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on December 6, 2022.

/s/ Charles B. O'Keeffe 12/08/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.